¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Specific disorder of arithmetical skills"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® cyclothymic disorder ÇÑ±Û ¼øÈ¯¼ºÀå¾Ö
¼³¸í   
  ¿ÜºÎÀڱؿ¡ ÀÇÇØ¼­ º¯È­ÇÏÁö ¾Ê´Â Áö¼ÓÀûÀΠ¸¶À½ÀÇ »óÅÂÀΠ±âºÐ(mood)ÀÇ ÀÌ»óÀÌ Àִ Á¤µ¿Àå¾Ö(affective disorder, mood disorder)ÀÇ ÇÑ Á¾·ù. Á¤µ¿Àå¾ÖÀÇ ´ëÇ¥ÀûÀΠº´À¸·Î´Â ¿ÜºÎÀÇ Àڱؿ¡ °ü°è¾øÀÌ Áö¼ÓÀûÀ¸·Î ±âºÐÀÌ ¿ì¿ïÇÑ ¿ì¿ïº´(depression)°ú Áö¼ÓÀûÀ¸·Î ¿ÜºÎÀÇ Àڱؿ¡ °ü°è¾øÀÌ ±âºÐÀÌ µé¶ß´Â Á¶º´(mania)ÀÌ ÀÖ´Ù. À̱ؼº Àå¾Ö¶õ ¿ì¿ïº´°ú Á¶º´ÀÌ ÁÖ±âÀûÀ¸·Î ¹Ýº¹µÇ´Â Á¤½Åº´°ú Á¶º´¸¸ ÀÖ°í ¿ì¿ïº´Àº ¾ø´Â °æ¿ì¸¦ ¸ðµÎ Æ÷ÇÔÇϴ °³³äÀÌ´Ù. Áï ¿ì¿ïº´ÀÇ À¯¹«¿¡ °ü°è¾øÀÌ Á¶º´ÀÌ ÇѹøÀ̶󵵠Àִ °æ¿ì À̰ÍÀ» À̱ؼº Àå¾Ö¶ó°í ÇÑ´Ù. ¼øÈ¯¼ºÀå¾Ö¶õ À̱ؼº Àå¾Ö¿Í °°ÀÌ ÈïºÐ°ú ¿ì¿ïÀÇ »óŰ¡ ÁÖ±âÀûÀ¸·Î ¹Ýº¹Çϴ °ÍÀº ¸¶Âù°¡ÁöÀÌÁö¸¸ ÈïºÐÀ̳ª ¿ì¿ïÀÇ »óŰ¡ ÈξÀ °æÇÑ °æ¿ì¿¡ »ç¿ëµÇ´Â ¸»ÀÌ´Ù.
  
  
¿µ¹® bipolar disorder ÇÑ±Û ¾ç±Ø¼º Àå¾Ö
¼³¸í   
  ¿ÜºÎÀڱؿ¡ ÀÇÇØ¼­ º¯È­ÇÏÁö ¾Ê´Â Áö¼ÓÀûÀΠ¸¶À½ÀÇ »óÅÂÀΠ±âºÐ(mood)¿¡ ÀÌ»óÀÌ Àִ Á¤µ¿Àå¾ÖÀÇ ÇÑ Á¾·ù. Á¤µ¿Àå¾ÖÀÇ ´ëÇ¥ÀûÀΠÁúȯÀ¸·Î´Â ¿ÜºÎÀÇ Àڱؿ¡ °ü°è¾øÀÌ ±âºÐÀÌ ¿ì¿ïÇÑ ¿ì¿ïÁõ(depression)°ú Áö¼ÓÀûÀ¸·Î ¿ÜºÎÀÇ Àڱؿ¡ °ü°è¾øÀÌ Áö¼ÓÀûÀ¸·Î ±âºÐÀÌ µé¶ß´Â Á¶Áõ(mania)ÀÌ ÀÖ´Ù. ¿ì¿ïÁõ°ú Á¶ÁõÀÌ ÁÖ±âÀûÀ¸·Î ¹Ýº¹ÀÌ µÇ´Â Á¤½ÅÁúȯ°ú Á¶Áõ¸¸ ÀÖ°í ¿ì¿ïÁõÀº ¾ø´Â °æ¿ì¸¦ ¸ðµÎ Æ÷ÇÔÇϴ °³³äÀÌ´Ù.
¿µ¹® language disorder ÇÑ±Û ¾ð¾îÀå¾Ö
¼³¸í   
  ¸»À» ¹Ù¸£°Ô ¹ßÀ½ÇÏÁö ¸øÇϰųª Á¤È®ÇϰԠÀÌÇØÇÏÁö ¸øÇϴ º´Áõ. ±³Åë¼ö´ÜÀ¸·Î¼­ÀÇ ¾ð¾î·Î Á¤º¸¸¦ Àü´ÞÇϴµ¥ À־ÀÇ Àå¾ÖÀÌ´Ù. ¾ð¾î¸¦ ÀÌÇØ, Ç¥ÃâÇϴ »ý¸®ÇÐÀû, ½É¸®ÇÐÀû, ¾ð¾îÇÐÀû, ¹°¸®ÇÐÀû, »çȸÇÐÀûÀΠ°¢ °úÁ¤¿¡¼­ÀÇ Áúº´À̳ª Àå¾Ö·Î ÀÎÇØ ÀϾ¸ç ±× ¿øÀÎÀ̳ª º´Å¿¡ µû¶ó ±¸À½Àå¾Ö, ¸»´õµë, À½¼ºÀå¾Ö, ¾ð¾î¹ß´ÞÁöü, Ã»·ÂÀå¾Ö, ¼±Ãµ±âÇü µî ¸¹Àº Áúº´, Àå¾Ö·Î ¼¼ºÐµÈ´Ù. ¿øÀΠ¹× º´ÅÂÀÇ °Ë»ç, Áø´Ü¿¡´Â ³»°ú, À̺ñÀÎÈİú, Á¤½Å°ú, Ä¡°ú µî ¿©·¯ °ú¸ñ¿¡ °ÉÃÄ Á¤¹ÐÁ¶»ç¸¦ ÇÔ°ú µ¿½Ã¿¡ ¾ð¾î±â´É°Ë»ç¸¦ ÇؾߠÇÑ´Ù.
¿µ¹® personality disorder ÇÑ±Û ÀΰÝÀå¾Ö, ¼º°ÝÀå¾Ö
¼³¸í   
  Å¸°í³­ Àμº°ú ¼ºÀå°úÁ¤ÀÇ ¿©·¯ »ç°Ç, ±×¸®°í ±³À°Á¤µµ¿¡ µû¶ó °³ÀÎÀÇ ÀΰÝÀº Çü¼ºµÈ´Ù. ÀÌ·± ÀΰÝ(¼º°Ý)ÀÌ »çȸ»ýȰ, È¤Àº °¡Á·»ýȰ¿¡ ÁöÀåÀ» Áְųª, ÀÚ±âÀÚ½ÅÀÇ »ýȰ¿¡ ÇÇÇØ¸¦ Áִ °æ¿ì, À̸¦ ÀΰÝÀå¾Ö¶ó ºÎ¸¥´Ù. ½ÇÁ¦·Î ÀÌ·± ÀÏ·ÃÀÇ ¼º°ÝµéÀº ´©±¸³ª Á¤»óÀûÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖÀ¸³ª, À̻󼺰ÝÀÌ ½ÉÇÑ °æ¿ì Ä¡·áÀÇ ´ë»óÀÌ µÈ´Ù.
¿µ¹® narcissistic personality disorder ÇÑ±Û ÀÚ±â¾ÖÀû ÀΰÝÀå¾Ö
¼³¸í   
  ÀÚ½ÅÀÇ Á߿伺°ú µ¶Æ¯ÇÔ, À¯ÀÏÇÔ¿¡ ´ëÇÑ ±¤ÀûÀΠÁýÂø°ú ÀÚ½ÅÀÌ ¼º°øÇÒ °ÍÀ̶ó´Â Áö³ªÄ£ ÁýÂøÀ» º¸¿©Áִ ¼º°ÝÀå¾Ö. Áö³ªÄ£ Àڱ⿡ÀÇ ¸¸Á·°¨À» °¡Áö°í, Áö³ªÄ£ Àڽۨ, ¼º°ø¿¡ ´ëÇÑ È®½ÅÀ» Áö´Ï°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific
    1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
  • specific absorption rate
    ºñÈí¼öÀ²
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
  • specific compliance
    ºñ¼øÀÀµµ
  • specific conductivity
    ºñÀüµµÀ²
  • specific death rate
    ƯÀÌ»ç¸Á·ü
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • specific fertility rate
    ƯÀÌ»ý½Ä·ü, ºñ»ý½Ä·ü
  • specific granule
    ƯÀ̰ú¸³
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cognitive disorder
    ÀÎÁöÀå¾Ö
  • communication disorder
    ÀÇ»ç¼ÒÅëÀå¾Ö
  • conversion disorder
    ÀüȯÀå¾Ö, Àüȯº´
  • coordination disorder
    Çùµ¿Àå¾Ö
  • delusional disorder
    ÆíÁýÀå¾Ö, ÆíÁýº´
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • language disorder
    ¾ð¾îÀå¾Ö
  • learning disorder
    ÇнÀÀå¾Ö
  • metabolic disorder
    ´ë»çÀå¾Ö
  • neuromuscular disorder
    ½Å°æ±ÙÀ°Àå¾Ö, ½Å°æ±ÙÀ°Áúȯ
  • obsessive-compulsive disorder
    °­¹ÚÀå¾Ö, °­¹Úº´
  • oppositional defiant disorder
    Àû´ëÀû¹ÝÇ×Àå¾Ö
  • panic disorder
    °øÈ²Àå¾Ö, °øÈ²º´
  • paranoid disorder
    (¢¡delusional disorder) ÆíÁýÀå¾Ö, ÆíÁýº´
  • personality disorder
    ÀΰÝÀå¾Ö, ¼º°ÝÀå¾Ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific charge
    °ßÁÜÀüÇÏ, ºñÀüÇÏ
  • specific compliance
    ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • donor-specific phage
    Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
  • specific disease
    ƯÀÌÁúȯ
  • specific reading disability
    ƯÁ¤ÀбâÀå¾Ö
  • group-specific
    ±ºÆ¯ÀÌ-
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific heat
    ƯÀÌ¿­
  • specific humidity
    ºñ½Àµµ
  • specific immunity
    ƯÀ̸鿪
  • specific inflammation
    ƯÀÌ¿°Áõ
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
  • Body dysmorphic disorder
    ½ÅüÀÌÇüÀå¾Ö(º´)
  • PDDs Pervasive Developmental Disorder
    Àü¹ÝÀû ¹ß´ÞÀå¾Ö
  • PTSD.see Post Traumatic Stress Disorder
    ¿Ü»óÈÄ ½ºÆ®·¹½ºÀå¾Ö(º´)
  • REM sleep behavior disorder
    ·½¼ö¸éÇൿÀå¾Ö(º´)
  • Retts disorder
    ·¹Æ®Àå¾Ö, ·¹Æ®º´
  • SAD, see seasonal affective disorder
    °èÀý¼º Á¤µ¿Àå¾Ö(º´)
  • acute brain disorder
    ±Þ¼º ³úÀå¾Ö (¡­Òàî¡äô).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bulk specific gravity
    ¿ëÀûºñÁß(é»îÝÝïñì)
  • donor-specific phage
    °ø¿©±ÕƯÀÌÆÄÁö
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
  • law of specific nerve energies
    Ư¼ö½Å°æ(÷åâ¨ãêÌè)¿¡³ÊÁöÀÇ ¹ýÄ¢.
  • liver specific protein
    °£Æ¯À̴ܹé
  • male-specific antigen
    ¿õ¼º¼¼Æ÷ƯÀÌÇ׿ø
  • neuron-specific enolase
    ´º¿ì·±Æ¯ÀÌ(¼º)¿¡³î¶óÁ¦
  • neutrophil specific antigen
    È£Áß±¸Æ¯ÀÌÇ׿ø.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
  • specific rate constant
    ƯÀÌ ¼Óµµ»ó¼ö(÷åì¶áÜÓøßÈâ¦)
  • specific reaction rate
    ƯÀÌ ¹ÝÀÀ¼Óµµ(÷åì¶ÚãëëáÜÓø)
  • specific refractive index increment
    ƯÀÌ ±¼ÀýÁö¼ö Áõ°¡(÷åì¶ÏÝï¹ò¦â¦ñòÊ¥)
  • specific retention volume
    ºñ Àú·ù ¿ëÀû(ÝïîÍ×µé»îÝ)
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
  • specific rotatory power
    ºñ¼±±¤·Â(ÝïàÁÎÃÕô)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DD dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional...
PAD pain and distress; patient surface axis depth; percutaneous abscess drainage; percutaneous automated...
HBsAg/adr hepatitis B surface antigen manifesting group-specific determinant a and subtype-specific determinan...
LSP left sacroposterior [fetal position]; linguistic string project; liver-specific protein; lymphocyte-...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AUDIT Alcohol Use Disorder Identification Test
APD Antisocial Personality Disorder
ASP Antisocial Personality Disorder
ASPD Antisocial Personality Disorder
ADD Attention Deficit Disorder
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific gamma emission
    Ư¼ö °¨¸¶ ¹æÃâ
  • specific gravity test
    ºñÁß ½ÃÇè
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • acquired disorder
    ÈÄõ¼º Àå¾Ö
    ¼±ÃµÀûÀÌ ¾Æ´Ï°í Ãâ»ý ÈÄ Á¤»óÀûÀÎ ¹ßÀ°¿¡ ÀÌ»óÀÌ »ý±â°Å³ª, º¯È­°¡ ¿À°Å³ª, Àå¾Ö°¡ ÀϾ °Í.
  • acute brain disorder
    ±Þ¼º ³úÀå¾Ö
  • adjustment disorder
    ÀûÀÀÀå¾Ö, ÀûÀÀÀå¾Ö º´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
poly(A)-specific ribonuclease <enzyme> From vigna unguiculata seedlings; bifunctional enzyme responsible for both poly(a)-polymerizing and poly(a)-hydrolyzing activities; removes the poly(a) tail as the first step in degrading mRNA
Registry number: EC 3.1.13.4
Synonym: poly(a) nuclease, mRNA poly(a) nuclease, poly(a) ribonuclease (pan), pan2 protein
(26 Jun 1999)
myelencephalon-specific serine protease <enzyme> Specifically expressed in the nervous system; plays a role in normal homeostasis and response of spinal cord to injury.
Registry number: EC 3.4.21.-
Synonym: myelencephalon-specific protease, msp enzyme
(26 Jun 1999)
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
species-specific Applying only to a particular species, said of effects that vary depending on the species in question.
(09 Oct 1997)
species-specific antigen Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á